A recent study showed that anti-PD-L1 monotherapy in patients with metastatic or unresectable CRC with mismatch repair deficiency (dMMR)/microsatellite instability-high (MSI-H) displayed remarkable anti-tumor activity with manageable toxicity [23]. The gene discussed is CD274; the disease is neoplasm.